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1.Introduction
Rodents are routinely used to evaluate the safety of pharmaceutical, industrial, and environmental agents. A substantial fraction of the tested chemicals target the liver due to the metabolic and detoxifying functions of this organ. Such biologically effective agents elicit hepatic responses, which maintain homeostasis (adaptive) or those that disrupt homeostasis (adverse) (Williams and Iatropoulos 2002) . Hepatic responses to xenobiotic exposure include the induction of biotransformation enzymes, activation of anti-oxidative stress response, liver enlargement, increased hepatic necrosis, and altered apoptosis or proliferation (Williams and Iatropoulos 2002) .
However, the underlying molecular mechanisms driving hepatic responses to xenobiotics are often not well defined. An improved understanding of these molecular mechanisms would facilitate the extrapolation of exposure outcomes from rodents to humans and improve risk assessment.
It has been suggested that miRNA, small non-coding genes which regulate protein levels at the post-transcriptional stage, could contribute to the cellular responses to toxicant exposures (Taylor and Gant, 2008) . Examining miRNA profiles could therefore enhance mechanistic understanding of how xenobiotics elicit their diverse effects on their target cells and tissues. Significantly, regulation by miRNA has been demonstrated to be crucial for the proper functioning of the liver, a complex organ with multiple key functions in physiology and disease. For example liver miRNAs are involved in the regulation of liver regeneration after hepatectomy (Chen et al., 2011; Song et al., 2010) , in hepatocyte differentiation and development (Gailhouste et al., 2013) , lipid and glucose metabolism (Esau at al., 2006; Trajkovski et al., 2013) , and bile acid homeostasis (Li et al., 2013) . Recently we reported for the first time an investigation into the effects of multiple chemicals with different modes of action on the liver miRNAome after three months of exposure (Koufaris et al., 2012) .
Importantly, all the tested chemicals affected the liver miRNAome, with the hepatic miRNA profiles being associated with their mode of action. However, reported studies so far have been limited to examining effects of a single dose of xenobiotics on the liver miRNAome at one or few time-points, which limits the ability to interpret 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 rationalization regarding the dosage levels and time-points to be used in studies investigating the contribution of miRNA to toxicological responses.
For this study we evaluated the expression of hepatic miRNAs of male Fischer rats dietary exposed to a control diet; a diet supplemented with a PB dose that induced centrilobular hypertrophy and weak CYP450 induction, but does not induce hepatomegaly or proliferation (50 parts per million (ppm)); or with two PB doses that cause strong CYP450 induction, hepatomegaly, and transient proliferation (500 and 1000 ppm). For each group miRNA profiles were assessed at 1, 3, 7 and 14 days. The effects of these PB treatments on liver growth, morphology, pathology, clinical parameters, metabolism, and expression of liver mRNAs in these animals were reported previously (Waterman et al.,2010) . Importantly, by the end of the 14 days alterations on liver growth and proliferation due to PB treatment were complete (Waterman et al.,2010) . Our analysis indicates that initially liver miRNA are relatively resistant to acute PB treatment, but more prominent, dose-dependent effects are observed following long-term treatments.
2.Materials and methods

Animal study
All animal procedures conformed to the Home Office (UK) guidelines for experimentation with animals and were approved by local ethics committee. Groups of six-week old male Fischer (F344) rats were obtained from Harlan Olac (Netherlands), randomly assigned to cages and treatment, and left to acclimatise for seven days prior to commencement of PB treatments. Three animals were examined per group. The rats were kept under controlled lighting (12h light cycles), humidity (30-70%), air flow (15 changes per hour), and temperature (22 ± 3 o C) conditions. Each group was exposed to different concentrations (0, 50, 500, 1000 ppm in the diet) of the sodium salt of phenobarbital which was added to the standard laboratory diet and milled to homogeneity. Rats were given access to mains water and powdered diet ad libitum. At the end of the study animals were killed midway through the light cycle to minimise circadian effects by an overdose of anaesthetic (halothane Ph.Eur.Vapour) followed by exsanguination after 1, 3, 7, 14 days of phenobarbital exposure. Control rats (0 ppm PB diet) were killed at each time point. Liver tissue   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 (left lateral lobe) was obtained from the animals immediately upon sacrifice, weighed, snap frozen and stored at -80C until needed. For some analyses, samples were also examined from rats treated in a separate study. In this additional study, groups of male Fischer (F344) rats (Harlan Olac) treated with PB (0, 50, 500 and 1000 ppm in the diet) for 28 and 90 days were used.
RNA extraction
Total RNA was extracted using Trizol (Invitrogen), following the manufacturer's instructions. RNA was used for subsequent analysis only if it had an RNA integrity number, as determined using an Agilent 2100 Bioanalyser and the RNA 6000 nano kit (Agilent), greater than eight and a 260:280 ratio greater than 2.0, as determined with a ND-1000 nanodrop spectrophotometer.
miRNA microarrays
The hepatic miRNAome was profiled at the MRC Genomics laboratory at Imperial
College London using the Agilent microRNA microarray platform as previously described (Koufaris et al., 2012) . Livers from three animals were examined per group.
The hybridisation data were extracted using the Agilent feature extraction software and normalised to the 75th percentile using Genespring GX (Agilent). For subsequent analysis we retained miRNAs which were flagged as present in at least two out of the three examined animals in any group. Box plots of normalized microarray data for individual samples displayed similar distributions supporting the quality of the hybridization data. The miRNA microarray data is available at Gene Expression 
Hierarchical clustering analysis
Hierarchical clustering analysis for mRNAs and miRNAs was performed in Cluster 3.0 using genes that had passed our filtering criteria. The probes were median centered and normalized and the tree was constructed using correlation centered as the similarity metric and average linkage.
Polymerase chain reaction (PCR)
For quantitative reverse-transcription real time PCR (qRT-PCR), total RNA was reverse transcribed using the miRNA reverse transcription kit (Agilent) and then amplified using the Taqman 
Immunoblotting
Livers were homogenised with a polytron machine (Labortechnik) in 500 μl of lysis buffer (50 mM Tris-HCl, pH 7.4; 1% IGEPAL (Sigma-Aldrich); 0.25% sodium deoxycholate (Sigma-Aldrich); 150 mM NaCl (Sigma-Aldrich); 1 mM EDTA (SIGMA-Aldrich); 100 X Halt Protease inhibitor (Pierce)). Homogenisation was followed by sonication and incubation at 4 °C for 30 min. The solutions were then centrifuged for 20 minutes to remove insoluble debris. The protein extracts were quantified using the BCA (bicinchoninic acid) protein assay (Pierce). Primary antibodies were purchased from Santa Cruz (Heidelberg) (zeb1 1:100, zeb2 1:100) or 
Global DNA methylation analysis
DNA was extracted from liver samples using the DNeasy Blood & Tissue kit (Qiagen) following the manufacturer's protocol, and using the reagents and buffers included in the kit. Extracted DNA was quantified using the Nanodrop ND-1000 and used for subsequent experiments if its 260:280 ratio was higher than 1.8. The levels of global DNA methylation for extracted DNA were determined using the Methylamp Global DNA Methylation Quantification Ultra Kit (Epigentek) following the manufacturer's instructions. This kit is based on the recognition of the methylated fraction of DNA by a labelled 5-methylcytosine which is subsequently quantified through an ELISA-like reaction.
Statistical analysis
Differentially expressed mRNAs and miRNAs were identified by one-way fixedmodel ANOVA with False Discovery Rate (FDR), the expected percentage of false positives within a given set of predicted differentially regulated genes, set to <0.1 in BRB-Array tools. The identified genes were then examined to determine whether they are over-represented for gene sets defined to be members of common biological pathways in the KEGG database using the ConsensuspathDB tool (Kamburov et al., 2009) . Similarly, enriched KEGG pathways for predicted and known targets of miRNAs were identified using miRSystem (Lu et al., 2012) and setting the threshold for a true target as being predicted by at least three software packages or being a verified target, an observed/expressed ratio above or equal to 2, and using pathways containing 25-500 genes. The student's T-test or Analysis of variance (ANOVA) was used to test for significance of all other analysis.
3.Results
Hierarchical clustering analysis of liver mRNA and miRNA profiles
As a first step towards evaluating the temporal effects of PB treatment we performed hierarchical clustering analysis on the liver miRNA and mRNA profiles, normalized to their respective time-point controls ( Fig.1A-B ; heatmap for miRNA clustering can be seen at Suppl. Fig.1 ). This analysis revealed a highly similar pattern of PB-induced perturbations on the liver miRNA and mRNA profiles, with a clear demarcation between acute (days 1-3) and sub-chronic (days 7-14 treatment). Importantly, the top pathway enriched for mRNA differentially expressed between livers exposed to acute
(1-3 days) and sub-chronic (7-14 days) PB treatments were the cell cycle and DNA replication (p<0.01) (Fig.1C) . Consequently, the dichotomy in mRNA and miRNA profiles between 1-3 days and 7-14 days of PB exposure relate to the liver switching from a proliferative to a non-proliferative state.
Moreover, hierarchical clustering analysis on individual days revealed a clear separation of the effect of PB doses on the liver miRNAome on the 14 th day of treatment (Fig.1D ), but was essentially random on the previous time-points (Suppl. Fig.2 ), indicating that the distinct effects of PB treatments on the liver miRNAome become more prominent with longer exposures. In contrast, clustering analysis based on hepatic mRNA profiles could discriminate the different PB doses already from day 3 of PB treatment (Fig.1E) . Therefore hierarchical clustering analysis supports a time-and-dose dependent pattern of effects on the liver miRNAome following PB treatment. Similarly, dosing with the drug induced time and dose-dependent effects on liver mRNAs, although prominent dose effects appeared to occur earlier for liver mRNAs compared to miRNAs.
Temporal analysis of mRNA expression compared to miRNA expression
We next aimed to identify significantly differentially expressed miRNA at each of the four time-points of the study. Our expectations were that we would detect both transient and persistent effects of PB on liver miRNA through the 14 days of the study. Surprisingly, using one-way ANOVA with FDR set at <10% no miRNAs were significant at days 1, 3, and 7, while there were 11 significant miRNAs at day 14. This was in contrast to the effects of the drug on liver mRNAs, were with the same analysis significantly deregulated genes could be identified from day 1 onwards (day 1 34 probes; day 3 156 probes; day 7 45 probes; day 14 195 probes). The relative expression of the significantly differentially expressed miRNAs at day 14 in the livers of animals treated with each PB dose can be seen in Table 1 .
In a previous study we had generated miRNA data from animals treated with 1000
ppm PB for a period of 90 days (Koufaris et al., 2012) . We therefore examined that dataset to determine whether the miRNA that we identified to be significantly differentially expressed at 14 days were also affected at that later time-point. In fact ,   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 the majority of miRNAs identified as significantly deregulated at 14 days displayed normal expression at 90 days of PB treatment ( we identified a progressive increase in expression from day 7 to day 90 of PB treatment ( Table 2) . Additionally, these miRNAs display a dose-dependent response to PB-treatment ( Fig.2A) and a highly correlated induction in response to PB treatment from day 7 to three months of PB treatment (Fig.2B) . Evaluation of hepatic miR-200b levels by qRT-PCR following PB treatment displayed highly similar levels to those determined by the miRNA microarray data, thus confirming the validity of the observed effects of PB treatment (Fig.2C) . The miRNAs miR-200a, miR-200b, and miR-429 are arranged in a chromosomal cluster with the mature miRNAs being processed from a single pri-miRNA regulated by a common promoter (Bracken et al.,2008) . Consequently the expressions of miRNA members of this chromosomal clusters miRNAs are highly correlated to each other. A similar arrangement into a common transcriptional unit also exists for miR-96 and miR-182 (Xu et al.,2007) . In this microarray dataset we did not detect miR-182 or miR-429, due to their lower expression and technical variability, although they are expected to be highly correlated with their co-clustered miRNAs. To prove the point we demonstrated by qRT-PCR the same dose-and-time dependent effects of PB treatment on miR-182 (Fig.2D ). It should be noted that the analysis of miR-182 in the samples at the 28 and 90 day time points were conducted on livers obtained from a different animal study to those used for the 1-14 day time points (Fig 2D) . 
Effect of PB on miRNA associated with hepatic proliferation
The two highest PB doses (500 and 1000ppm) caused a transient increase in hepatic proliferation that peaked on the third day of treatment (39% and 61% increase in Ki67 labelling index) (Waterman et al.,2010) . However, our previous analysis did not identify any differentially regulated miRNA at the early time-points (days 1-3). We then decided to inspect the effect of the proliferation-inducing PB doses on selected miRNA that had been previously associated with hepatic proliferation following peroxisome proliferator-activated receptors (pparα) activation or liver regeneration after hepatectomy. However, none of these miRNA were affected in our dataset by the proliferation-inducing PB treatments (Suppl. Table 2 ), indicating that they are not involved in this phenotype.
Association between miR-29b with global hepatic DNA methylation and miR200a/200b with zeb1/zeb2 transcription factors
In the microarray dataset hepatic miR-29b was transiently repressed by PB treatment at 14 days of treatment (Fig 3A) . Importantly, miR-29b has been reported to be master regulator of global DNA methylation (Fabbri et al., 2007; Garzon et al., 2009 ).
Interestingly, PB treatment is known to affect DNA methylation patterns in the liver (Counts et al.,1996) , leading us to enquire whether there existed an association between miR-29b and global DNA methylation. Indeed, in agreement with the reported activity of miR-29b to antagonise global DNA methylation the transient repression of this miRNA at day 14 of PB treatment was associated with a transient increase in global DNA methylation (Fig. 3B) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 treatment ( Fig. 4A-B) , consistent with an inverse association to the dose-dependent induction of the miR-200 family at that timepoint ( Fig. 2A) . However there was no associated change in the expression levels of hepatic e-cadherin, a key epithelial marker that is downstream of zeb1 and zeb2 ( Fig. 4C-D) .
Epithelial to mesenchymal transition (EMT) is
Discussion
To the best of our knowledge this is the first study to investigate both the temporal and dose effects of xenobiotic treatments on the liver miRNAome. Significantly, in agreement with other studies examining the effects of acute dioxin, benzo(a)pyrene, and N-ethyl-N-nitrosourea exposures (Moffat et al., 2007; Li et al., 2010; Yauk et al., 2010) liver miRNA were initially relatively unresponsive to chemical treatment compared to liver mRNA (Fig.1 ). This observation suggests that liver miRNA networks are under particularly stringent regulation, perhaps due to their important master-regulatory functions. However, after sub-chronic (>one week) PB-treatment, liver miRNA deregulation clearly becomes more prominent and dose-dependent ( Fig.   1-2 ; Table 1 -2). Interestingly, the initiation of more prominent changes in hepatic miRNA coincides temporally with the achievement of equilibrium (termination of the proliferation and achievement of maximum hepatomegaly) in the liver of animals being continuously exposed to PB. This observation raises the interesting possibility that the predominant role of miRNA in response to xenobiotics in the adult liver may be to direct homeostatic adaptation to sub-chronic and chronic exposures.
Consequently, our PB data suggest that studies interested in investigating the role of miRNA in liver response to xenobiotics should focus more on the effects of high dose/long term exposures. However, more studies are needed to determine whether the time and dose dynamics of PB-miRNA interaction identified here reflect the majority of xenobiotic agents targeting the liver.
We had previously identified the co-ordinated increased expression of the hepatic miR-200a/200b/429 and miR-96/182 miRNA clusters specifically in the livers of animals treated for 90 days with PB, di(2-ethylhexyl)phthalate, and benzophenone (Koufaris et al.,2012) . That observation led us to hypothesize that the co-ordinated upregulation of these miRNA clusters could be characteristic of nuclear-receptor agonists. Another commonality of these chemicals is that they induce a transient 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 hepatic proliferative response. Interestingly, from this study that this miRNA response (i) is temporally associated with the termination of the PB-induced proliferation (initiated after 7-14 days) (ii) is persistant and progressive (iii) occurs only in response to proliferation-inducing 500 and 1000 ppm PB doses (Fig.2) . The coordinated upregulation of this miRNA clusters could therefore be a molecular signature of the liver adapting to xenobiotic-induced transient hyperplasia. However, it is unclear whether this miRNA response is causally involved in this hepatic response. We have also associated PB-induced deregulation of miR-29b and miR200a/200b/429 with altered global DNA methylation and repression of the zeb1/zeb2 transcription factors (Fig.3-4) . The functional importance of these miRNA deregulations is not clear at present. However, it is important to note that both DNA methylation and EMT have been associated with PB-induced carcinogenicity. Global hypomethylation is more pronounced in PB-treated livers of mice strains susceptible to PB-treated carcinogenesis (Counts et al., 1996) . Similarly, EMT has been reported to be strongly activated in mice susceptible to PB-induced hepatocarcinogenicity (Phillips et al.,2009) . It should be noted that PB is an established non-genotoxic hepatocarcinogen in some mice strains, but not in rats (Whysner et al.,1996) . Recently (and the subsequent repression of zeb1/zeb2) may be to contribute to the protection of the epithelial nature of hepatocytes exposed to biologically effective levels of xenobiotics. However, it is not clear if that is the main effect of miR-200 in PB treated livers, as we did not observe here any associated changes in the expression of the epithelial gene e-cadherin, It will be an interesting avenue for future work to investigate whether miRNA are involved in the different susceptibilities of mice and rats to PB-induced carcinogenicity .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 A better comprehension of the molecular mechanisms driving liver responses to exogenous agents will be highly important for predicting the toxic side-effects of xenobiotic exposures, for extrapolating the effects of the exposures across species, and for enhancing understanding of fundamental liver biology. In this study we have identified a complex pattern of PB-treatment related effects on the liver miRNAome.
Given the key regulatory role of miRNAs, alterations in the expression of these genes could be an important molecular mechanism by which the liver initiates and sustains responses to the drug. More generally, we have now performed two studies, here and Koufaris et al., (2012) , which enhance our understanding of the effects of xenobiotic treatments on liver miRNAs. In unison our data demonstrate that hepatic miRNA expression changes are affected by xenobiotics; are dependent on the dose; are temporally regulated; indicate the mode of action of chemicals; and have important phenotypic effects. These fundamentally important observations support the need for further investigation into the regulatory functions of hepatic miRNAs that will enhance our understanding of the adaptive and adverse hepatic responses to xenobiotic exposures. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65 
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